TY  - JOUR
A1  - Volkmann, Jens
A1  - Albanese, Alberto
A1  - Antonini, Angelo
A1  - Chaudhuri, K. Ray
A1  - Clarke, Karl E.
A1  - de Bie, Rob M. A.
A1  - Deuschl, Günther
A1  - Eggert, Karla
A1  - Houeto, Jean-Luc
A1  - Kulisevsky, Jaime
A1  - Nyholm, Dag
A1  - Odin, Per
A1  - Ostergaard, Karen
A1  - Poewe, Werner
A1  - Pollak, Pierre
A1  - Rabey, Jose Martin
A1  - Rascol, Olivier
A1  - Ruzicka, Evzen
A1  - Samuel, Michael
A1  - Speelman, Hans
A1  - Sydow, Olof
A1  - Valldeoriola, Francesc
A1  - van der Linden, Chris
A1  - Oertel, Wolfgang
T1  - Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review
JF  - Journal of Neurology
N2  - Motor complications in Parkinson’s disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine.
KW  - Parkinson’s disease
KW  - apomorphine
KW  - deep brain stimulation
KW  - duodenal levodopa infusion
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-132373
VL  - 260
ER  - 
TY  - JOUR
A1  - Odin, Per
A1  - Chaudhuri, K. Ray
A1  - Volkmann, Jens
A1  - Antonini, Angelo
A1  - Storch, Alexander
A1  - Dietrichs, Espen
A1  - Pirtošek, Zvezdan
A1  - Henriksen, Tove
A1  - Horne, Malcolm
A1  - Devos, David
A1  - Bergquist, Filip
T1  - Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease
JF  - npj Parkinson's Disease
N2  - Motor aspects of Parkinson’s disease, such as fluctuations and dyskinesia, can be reliably evaluated using a variety of “wearable” technologies, but practical guidance on objective measurement (OM) and the optimum use of these devices is lacking. Therefore, as a first step, a panel of movement disorder specialists met to provide guidance on how OM could be assessed and incorporated into clinical guidelines. A key aspect of the incorporation of OM into the management of Parkinson’s disease (PD) is defining cutoff values that separate “controlled” from “uncontrolled” symptoms that can be modified by therapy and that relate to an outcome that is relevant to the person with PD (such as quality of life). Defining cutoffs by consensus, which can be subsequently tested and refined, is the first step to optimizing OM in the management of PD. OM should be used by all clinicians that treat people with PD but the least experienced may find the most value, but this requires guidance from experts to allow non-experts to apply guidelines. While evidence is gained for devices that produce OM, expert opinion is needed to supplement the evidence base.
KW  - Parkinson's disease
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-234435
VL  - 4
ER  -